While wild‐type p53 protein is regarded as “a guardian of the genome” by inducing cell cycle arrest and DNA repair,5, 6 p53 mutation not only abrogates the wild‐type activity of p53, but also endows mutant p53 with oncogenic function, namely “gain of function,” to promote metastasis and chemoresistance of ovarian cancer.7, 8, 9. This evidence concerns the gene TP53 and ovarian cancer.